Search research articles
Contact Us
Filters
Showing results (351-360 of 368) with videos related to
Page
of 37
Sort By:
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer
|
July 30, 2005
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
P F Conte, S Donati, A Gennari, et al.
Translational Psychiatry
|
July 6, 2021
Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936
O K L Hamilton, S R Cox, J A Okely, et al.
Gynecologic Oncology
|
June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest
M Bruzzone, A Rubagotti, A Gadducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2020
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
F André, E M Ciruelos, D Juric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
D Nitti, J Wils, J Guimaraes Dos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2000
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
H von der Maase, S W Hansen, J T Roberts, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 368) with videos related to
Sort By:
Page
of 37
Cancer Treatment Reviews
|
January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
July 3, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
Cancer Treatment Reviews
|
May 7, 2023
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
F Miglietta, A Fabi, D Generali, et al.
British Journal of Cancer
|
July 30, 2005
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
P F Conte, S Donati, A Gennari, et al.
Translational Psychiatry
|
July 6, 2021
Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936
O K L Hamilton, S R Cox, J A Okely, et al.
Gynecologic Oncology
|
June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest
M Bruzzone, A Rubagotti, A Gadducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2020
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
F André, E M Ciruelos, D Juric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
D Nitti, J Wils, J Guimaraes Dos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2000
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
H von der Maase, S W Hansen, J T Roberts, et al.
Page
of 37